USANA Health Sciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from USANA Health Sciences, Inc.'s yearly results (2022–2025), compared with Consumer Defensive companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 52% of its market value (net cash). Higher than 97% of Consumer Defensive companies in United States.
- Steadiness Ratio: Sales grew in 1 of the last 3 years; profit grew in 0 of 3. Less steady than 93% of Consumer Defensive companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$132Over the last 3 years, every $100 of reported profit came with $132 of operating cash.
Lower than 71% of Consumer Defensive companies in United States.
Self-Funding Ratio
4.0×Over the last 3 years its own operating cash covered its investment spending (capex) 4.0 times.
Higher than 73% of Consumer Defensive companies in United States.
Cash Locked Ratio
$9For every $100 of sales, $9 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $5 tied up three years earlier.
Less money tied up than 51% of Consumer Defensive companies in United States.
Growth quality
Steadiness Ratio
1/3 · 0/3Sales grew in 1 of the last 3 years; profit grew in 0 of 3.
Less steady than 93% of Consumer Defensive companies in United States.
Growth Efficiency Ratio
—Sales fell 7%
Sales fell 7% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-7% / +25%In 3 years sales changed by -7% while total assets changed by +25%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
1.6×Debt due within a year is covered 1.6 times by its yearly operating cash.
Lower than 64% of Consumer Defensive companies in United States.
Cash Cushion Ratio
+52%Cash, after subtracting all debt, equals 52% of its market value (net cash).
Higher than 97% of Consumer Defensive companies in United States.
Tangible Assets Ratio
64%Of every $100 the company owns, $64 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 69% of Consumer Defensive companies in United States.
Tangible Net Worth Ratio
49%Of every $100 of net worth, $49 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 53% of Consumer Defensive companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
USANA Health Sciences, Inc. made a loss over the last year. USANA Health Sciences, Inc. owes $0.19 for every $1 it owns. Net profit fell 74% in the year to Dec 2025, and shrank 46% a year on average over 3 years.
Compared with Consumer Defensive companies in United States · latest annual results Dec 2025.
P/E ratio
LossUSANA Health Sciences, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.51The share price is 0.51 times USANA Health Sciences, Inc.'s book value per share, lower than 88% of Consumer Defensive companies in United States.
Market cap
$268 MThe total market value of all of USANA Health Sciences, Inc.'s shares at today's price (share price × number of shares), smaller than 68% of Consumer Defensive companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$526 MWhat USANA Health Sciences, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$28.49Net worth divided by the number of shares. The share price of $14.52 is 0.5 times this, which is the P/B above.
Return on equity (ROE)
-5.1%USANA Health Sciences, Inc. lost 5.1% of its shareholders' money over the last year, lower than 66% of Consumer Defensive companies in United States.
Owes vs Owns
0.19×USANA Health Sciences, Inc. owes $0.19 for every $1 it owns (low), lower than 94% of Consumer Defensive companies in United States.
Dividend yield
NoneUSANA Health Sciences, Inc. does not currently pay a dividend.
Revenue growth
+8%Revenue rose 8% in the year to Dec 2025, and shrank 3% a year on average over 3 years.
Profit growth
-74%Net profit fell 74% in the year to Dec 2025, and shrank 46% a year on average over 3 years.
Profit margin
1.2%USANA Health Sciences, Inc. keeps $1 of every $100 of revenue as net profit.
Cash quality
2.1×Cash from USANA Health Sciences, Inc.'s business was 2.1× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
60.4×USANA Health Sciences, Inc.'s operating profit covered its interest costs 60.4 times in the year to Dec 2025.
Cash vs debt
Net cashUSANA Health Sciences, Inc. held $139 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For USANA Health Sciences, Inc.: $268 M ÷ $526 M (30 Jun 2026) = 0.5.
What is USANA Health Sciences, Inc.'s return on equity?
USANA Health Sciences, Inc. lost 5.1% of its shareholders' money over the last year, lower than 66% of Consumer Defensive companies in United States.
How much does USANA Health Sciences, Inc. owe compared with what it owns?
USANA Health Sciences, Inc. owes $0.19 for every $1 it owns (low), lower than 94% of Consumer Defensive companies in United States.
Does USANA Health Sciences, Inc. pay a dividend?
No. USANA Health Sciences, Inc. does not currently pay a dividend.
Is USANA Health Sciences, Inc.'s revenue growing?
Revenue rose 8% in the year to Dec 2025, and shrank 3% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.